Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Buys Cancer Dx Rights from SourceMDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing technology company DxTerity Diagnostics said today that it has acquired the intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx.

The IP covers gene expression assays for early diagnosis of breast and lung cancer and a test for determining survival and response to therapy for melanoma patients. They are covered by a portfolio of more than 30 US and international patent filings.

The Los Angeles-based firms said that it has begun migrating these tests to function on its Non-Enzymatic Amplification Technology (NEAT) platform, which is designed to make genetic testing easier and cheaper.

The NEAT technology eliminates the need for sample purification and enzymatic amplification, and it is based on technology DxTerity has licensed from Stanford University, where it was developed.

"The NEAT platform is perfect for blood-based genomic testing since it enables the simultaneous direct-from-sample measurement of up to 40 gene targets," DxTerity CEO Bob Terbrueggen said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.